Status:
WITHDRAWN
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Lead Sponsor:
Children's Hospital of Philadelphia
Conditions:
Desmoid Tumors
Fibromatosis
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the response rate of desmoid tumors to hydroxyurea. The investigators hypothesize that hydroxyurea will be a safe, non-toxic alternative to aggressive surgery o...
Detailed Description
The treatment of desmoid tumors is complicated by benign histology and potentially aggressive and recurrent behavior. Invasive or intensive treatments with surgery or radiation therapy can lead to goo...
Eligibility Criteria
Inclusion
- Patients \</= 21 years of age will be eligible
- Histologically-confirmed diagnosis of desmoid tumor
- Measurable disease
- Stable hematologic, renal and hepatic parameters
- Negative pregnancy test for women of childbearing potential
Exclusion
- Presence of a second neoplastic process
- Pregnant or breastfeeding women, fetuses, and prisoners will not be included in this study
- Patients receiving additional treatment for tumor other than pain control
- Patients having taken an investigational drug within the past 30 days
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00978146
Start Date
October 1 2009
End Date
January 1 2015
Last Update
April 20 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.